Evidence map›Paper›PMID 38461845›Full record

ArticleThe lancet. HIV2024

Low-cost urine tenofovir assay to triage dolutegravir resistance testing.

Tyler Martinson, Jacinta Nwogu-Attah, Matthew Spinelli, Monica Gandhi

Open access · greenAbstract readLetter
In one paragraph

Article in The lancet. HIV, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. A Real-Time Urine Tenofovir Assay Improves Drug Adherence Among People With HIV With Prior Virologic Failure in a Randomized Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Trial
  2. Trial
  3. Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tyler MartinsonDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA; Department of Internal Medicine, Kaiser Permanente San Francisco, San Francisco, CA, USA.
Jacinta Nwogu-AttahFaculty of Pharmacy, Pharmaceutical Chemistry Department, Lead City University, Ibadan, Nigeria.
Matthew SpinelliDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California San Franscico, San Francisco, CA 94110, USA.
Monica GandhiDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA; Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California San Franscico, San Francisco, CA 94110, USA. Electronic address: monica.gandhi@ucsf.edu.
Lead City University · NG

Funding

Randomized Trial to Optimize Virologic Suppression Rates Using a Point-of-Care Urine Monitoring Assay (ROVING-PUMA)R01AI143340 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2018 to 2026
$5.6M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
NIAID NIH HHS R01 AI143340NIAID NIH HHS R37 AI098472
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug Resistance, ViralHeterocyclic Compounds, 3-RingHIV InfectionsOxazinesPiperazinesPyridonesTenofovirAnti-HIV AgentsDolutegravirHIV-1HIV Integrase InhibitorsHumansAnti-HIV AgentsDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsOxazinesPiperazinesPyridonesTenofovir

Identifiers

PMID38461845
PMCPMC11663141
OpenAlexW4392564462

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.